Vitrivax

• ·Vitrivax’s last known valuation is $69.4M (Nov 2025).
• ·It has raised $38.2M across 1 recorded rounds; the latest was Later Stage VC (Series B) ($29.4M) in Nov 2025.
• ·Notable investors include RA Capital Management, Gates Foundation, Fox Ventures, Colorado Office of Economic Development & International Trade, Coalition for Epidemic Preparedness Innovations — 15 tracked in total.
• ·1 investment vehicle was formed to buy Vitrivax shares in the last 12 months, reporting $217K sold to 15 investors, per SEC Form D filings.
• ·Vitrivax has filed 1 Form D with the SEC, most recently Nov 2025 ($29.4M sold to 83 investors).
• ·Status: Privately Held (backing).

In the last 12 months, 1 investment vehicle were formed to buy Vitrivax shares, reporting $217K sold to 15 investors. Most recent filing Oct 2025. Vehicles like these are how secondary buyers pool demand for a name; a rising count is a demand signal.

Developer of thermostable vaccine formulations designed to eliminate barriers to global vaccination. The company offers a proprietary atomic-layering thermostable antigen and adjuvant technology platform to enable thermostable, single-shot vaccines across a broad range of indications while maintaining or potentially even enhancing the immune response, enabling users to incorporate prime doses and additional booster doses in a single-shot administration.

Industry

Discovery Tools (Healthcare)

Sector

Healthcare

HQ

Boulder, CO, United States

Founded

2014

Employees

52

Website

vitrivaxbio.com/

Ownership

Privately Held (backing)